Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients

被引:18
|
作者
Kosmalski, M. [1 ]
Drozdowska, A. [1 ]
Sliwinska, A. [1 ]
Drzewoski, J. [1 ]
机构
[1] Med Univ Lodz, Dept Internal Dis Diabetol & Clin Pharmacol, PL-95100 Zgierz, Poland
来源
ADVANCES IN MEDICAL SCIENCES | 2012年 / 57卷 / 01期
关键词
diabetes mellitus; metformin; off - label use; prescription; side effects; LACTIC-ACIDOSIS; CONTRAINDICATIONS; THERAPY; RISK;
D O I
10.2478/v10039-012-0017-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: Metformin is the most commonly prescribed anti-diabetic medication. However, it is often used despite the presence of contraindications and in unlicensed indications. The main aim of this study was to evaluate the frequency of metformin use before hospitalization in spite of contraindications in patients with type 2 diabetes mellitus (T2DM) and to evaluate the prevalence of metformin -associated side effects. Material/Methods: 558 hospitalized patients (mean age = 66.65 +/- 12.73 years) with poorly controlled T2DM were enrolled. Detailed medical history including the duration of T2DM, duration of hypoglycemic agents usage prior to hospitalization and possible metformin-associated side effects was recorded. Patients were subjected to a thorough physical examination and indispensable biochemical and diagnostic research panel was performed to establish the degree of heart failure, sufficiency of the respiratory system and kidney function. Results: 335 out of 558 patients were treated before hospitalization with metformin alone or in combination with other hypoglycemic agents, mostly sulfonylureas. Contraindications to metformin were found in 275 patients and despite this 120 of them were using this medication in an average dose of 1793.91 +/- 701.61 mg. However, none of them reported any serious adverse effects and no significant pH changes were observed. Only three patients reported moderate dyspepsia. Conclusions: The results of this study indicate a relatively good tolerability of metformin by patients with the traditional contraindications to this drug. These findings support other authors' suggestion that indications and contraindications to metformin should be re-evaluated.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 50 条
  • [1] Safety and Tolerability of Linagliptin and Metformin in Combination for Patients with Type 2 Diabetes Mellitus (T2DM)
    Ross, Stuart A.
    Haak, Thomas
    Patel, Sanjay
    Thiemann, Sandra
    Schumacher, Helmut
    Meinicke, Thomas
    DIABETES, 2014, 63 : A277 - A277
  • [2] The Usage of Metformin Despite of Existing Contraindications in Type 2 Diabetes Mellitus (T2DM) Patients
    Kosmalski, Marcin
    Drozdowska, Agata
    Drzewoski, Jozef
    DIABETES, 2011, 60 : A311 - A312
  • [3] Retrospective study of type 2 diabetes mellitus (T2DM) patients not optimally controlled by metformin monotherapy
    He, J.
    Neslusan, C.
    VALUE IN HEALTH, 2008, 11 (03) : A18 - A18
  • [4] Augmentation Patterns Amongst Metformin Initiators with Type 2 Diabetes Mellitus (T2DM)
    Gopalakrishnan, Chandrasekar
    Schneeweiss, Sebastian
    Seeger, John D.
    Liu, Jun
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 26 - 27
  • [5] Efficacy of metformin alone or in combination with insulin in pediatric patients with type 2 diabetes mellitus (T2DM)
    Weinzimer, SA
    McKnight, WJ
    Murphy, K
    Jawad, AF
    Celona-Jacobs, N
    Haque, A
    Katz, LEL
    DIABETES, 2001, 50 : A68 - A68
  • [6] Effects on lipid metabolism of metformin and troglitazone, alone and in combination, in patients with type 2 diabetes mellitus (T2DM)
    Lee, I
    Maggs, DG
    Katz, D
    Spollett, GR
    Page, SL
    Rife, FS
    Inzucchi, SE
    DIABETES, 2002, 51 : A105 - A105
  • [7] Pharmacogenomics and pharmacomicrobiomics in type 2 diabetes mellitus (T2DM)
    Luo, Jian-Quan
    Shu, Yan
    Zhang, Wei
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [8] Vascular responsiveness in type 2 diabetes mellitus (T2DM)
    Blum, A.
    Socea, D.
    Sirchan, R.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016, 109 (12) : 791 - 796
  • [9] The platelets characteristics in type 2 diabetes mellitus (T2DM)
    Buryachkovskaya, L.
    Uchitel, I. A.
    Sumarokov, A. B.
    Docenko, U., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931
  • [10] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    FASEB JOURNAL, 2002, 16 (04): : A208 - A208